ストックスクリーナーアプリを入手
51.59
2.44%
1.23
アフターアワーズ：
50.53
-1.06
-2.05%
Crispr Therapeutics Ag (CRSP) 最新ニュース
Better Gene-Editing Stock: CRISPR Therapeutics or Beam Therapeutics? - The Motley Fool
Gene Editing Sector Gains Momentum with Key Players CRISPR and Beam - Intellectia AI
Better Gene-Editing Stock: CRISPR Therapeutics or Beam Therapeutics? - The Motley Fool
CRISPR Therapeutics’ SWOT analysis: gene therapy stock faces competitive pressures - Investing.com Nigeria
Needham Maintains CRISPR Therapeutics (CRSP) Buy Recommendation - MSN
Assessing CRISPR Therapeutics (CRSP) Valuation After Narrower Q1 2026 Loss And Pipeline Progress - Yahoo Finance
CRISPR Therapeutics AG - TradingView
Beck Bode LLC Buys New Shares in CRISPR Therapeutics AG $CRSP - MarketBeat
Precision Trading with Crispr Therapeutics Ag (CRSP) Risk Zones - Stock Traders Daily
CRISPR Therapeutics AG (CRSP) Reports Q1 2026 Results - Insider Monkey
A Look At CRISPR Therapeutics (CRSP) Valuation As CASGEVY Rollout And Earnings Revisions Renew Investor Interest - Sahm
Bernstein Raises its Price Target on CRISPR Therapeutics (CRSP) - Insider Monkey
Leonteq Securities AG Makes New Investment in CRISPR Therapeutics AG $CRSP - MarketBeat
CRISPR Therapeutics AG $CRSP Shares Bought by Northwestern Mutual Wealth Management Co. - MarketBeat
Crispr Therapeutics remains a Buy with strong pipeline and cash despite slow Casgevy uptake. - Pluang
CRSP Technical Analysis | Trend, Signals & Chart Patterns | CRISPR THERAPEUTICS AG (NASDAQ:CRSP) - ChartMill
These Are The Upcoming Catalysts For Crispr Therapeutics Stock (NASDAQ:CRSP) - Seeking Alpha
CRISPR Therapeutics enters 'second phase' as CASGEVY momentum builds, pipeline data looms - MSN
1 Top Wall Street Analyst Thinks CRISPR Therapeutics Could More Than Double. Should You Buy the Stock Hand Over Fist? - AOL.com
CRSP News | CRISPR THERAPEUTICS AG (NASDAQ:CRSP) - ChartMill
Can Intellia's Pipeline Push Drive Long-Term Growth Amid Rivalry? - Yahoo Finance Singapore
CRISPR Therapeutics AG (CRSP) is attracting investor attention: Here is what you should know - MSN
CRISPR Therapeutics AG (CRSP) is Attracting Investor Attention: Here is What You Should Know - Yahoo Finance
CRISPR Therapeutics stock (CH0334081137): gene-editing pioneer ahead of next earnings test - AD HOC NEWS
1 top Wall Street analyst thinks CRISPR Therapeutics could more than double. Should you buy the stock hand over fist? - MSN
CRISPR Therapeutics AG (CRSP) Stock Drops Despite Market Gains: Important Facts to Note - MSN
Baird Maintains CRISPR Therapeutics (CRSP) Neutral Recommendation - MSN
CRISPR Therapeutics AG (HAM:1CG) Cyclically Adjusted Price-to-FCF : (As of May. 18, 2026) - GuruFocus
Is CRISPR (CRSP) Quietly Rewriting Its Gene‑Editing Priorities After Narrower Losses and Casgevy Progress? - simplywall.st
CRISPR Therapeutics AG Trade Ideas — SWB:1CG - TradingView
symbol__ Stock Quote Price and Forecast - CNN
CRISPR Therapeutics Enters 'Second Phase' as CASGEVY Momentum Builds, Pipeline Data Looms - MarketBeat
Orbis, Allan Gray report 6.3% stake in CRISPR Therapeutics (CRSP) - Stock Titan
Analysts Are Bullish on These Healthcare Stocks: Crispr Therapeutics AG (CRSP), Caris Life Sciences, Inc. (CAI) - The Globe and Mail
CRISPR Therapeutics AG (CRSP) exceeds market returns: Some facts to consider - MSN
Capital World Investors discloses 5.1% stake in CRSP (4.93M shares) - Stock Titan
CRISPR Therapeutics stock (CH0334081137): Bernstein raises price target amid gene-editing momentum - AD HOC NEWS
CRSP Maintained by Bernstein -- Price Target Raised to $56 - GuruFocus
Vanguard Group Inc. Reduces Stock Position in CRISPR Therapeutics AG $CRSP - MarketBeat
Technical Reactions to CRSP Trends in Macro Strategies - Stock Traders Daily
Why Is CRISPR Therapeutics Stock in Focus Right Now - Kalkine Media
CRISPR Therapeutics AG (NASDAQ:CRSP) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat
Why the market dipped but CRISPR Therapeutics AG (CRSP) gained today - MSN
0.98%
0.12%
大文字化:
|
ボリューム (24 時間):